HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

Ovarian clear cell adenocarcinoma (CCA) is generally chemo‐resistant. Recently the poor prognosis and resistance to chemotherapeutic agents of HER2/neu over‐expressing tumors have become clear. Thus, we investigated the expression level of HER2 in surgically resected CCA and ovarian serous adenocarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Masaki, Katsumata, Noriyuki, Tsuda, Hiroshi, Uchi, Naoko, Miyazaki, Satomi, Hidaka, Takao, Sakai, Masatoshi, Saito, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2002
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926901/
https://www.ncbi.nlm.nih.gov/pubmed/12460467
http://dx.doi.org/10.1111/j.1349-7006.2002.tb01231.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926901/
https://www.ncbi.nlm.nih.gov/pubmed/12460467
http://dx.doi.org/10.1111/j.1349-7006.2002.tb01231.x

Ejemplares similares